Sangamo Therapeutics Inc (SGMO) — Capital Reinvestment Ratio

Latest as of September 2024: 0.01x

Sangamo Therapeutics Inc (SGMO) has a Capital Reinvestment Ratio of 0.01x as of September 2024, meaning it reinvests 0% of its operating cash flow ($11.76 Million) in capital expenditures ($115.00K). Check SGMO intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.01x
Capex / Operating Cash Flow

Operating Cash Flow

$11.76 Million
USD

Capital Expenditures

$115.00K
USD

Data as of

Sep 2024
Most recent filing

Sangamo Therapeutics Inc Capital Reinvestment Ratio (2017–2020)

This chart tracks Sangamo Therapeutics Inc's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see SGMO cash flow conversion.

Annual Capital Reinvestment Ratio for Sangamo Therapeutics Inc (2017–2020)

Year-by-year Capital Reinvestment Ratio for Sangamo Therapeutics Inc from 2017 to 2020. See Sangamo Therapeutics Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2020 0.09x $169.88 Million $14.71 Million ▼ -92.5%
2018 1.16x $37.15 Million $43.06 Million ▲ +245.5%
2017 0.34x $11.18 Million $3.75 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow